Arcus Biosciences, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Arcus Biosciences, Inc. (RCUS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 3.10% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2021-02-25
- Arcus Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was 3.10%.
- Arcus Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2019 was 0.00%.
- Arcus Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2018 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2020-12-31 | 3.10% 10-K · filed 2021-02-25 |
| 2019-12-31 | 0.00% 10-K · filed 2021-02-25 |
| 2018-12-31 | 0.00% 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |